1. Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada. (1st December 2020) Authors: Nakhaipour, Hamid Reza; Vudumula, Umakanth; Khurana, Vivek; Sébire, Guillaume; Mah, Jean K.; Pohl, Daniela; Schecter, Robyn; Adlard, Nicholas Journal: Journal of medical economics Issue: Volume 23:Number 12(2021) Page Start: 1525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗